Hunter Associates Investment Management LLC reduced its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 23.6% in the fourth quarter, according to the company in its most recent filing with the ...
Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.
Recent health news highlights include a review of the safety of Alzheimer's drug Leqembi, legal charges against a New York ...
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...
In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback